endocrinology
Osteoporosis

New guidelines recommend zoledronate after denosumab withdrawal

Osteoporosis patients who discontinue denosumab therapy after long term use should be treated with zoledronate to prevent a rebound increase in bone turnover and a rapid bone loss, new guidelines advise. The new advice from the European Calcified Tissue Society (ECTS) follows the publication of data from the ZOLARMAB trial, which investigated the effects of ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic